IBSP and non-small cell lung carcinoma: Exogenous recombinant BSP enhances anoikis resistance (a form of programmed cell death due to detachment) in NSCLC cells (A-549 and CL1-5) in a dose- [0–30 ng/mL (0–0.3 μg/mL)] and time-dependent (1, 2 and 3 days) manner.135 Anoikis-resistant cells exhibit changes in epithelial-mesenchymal transition (EMT) markers, including increased vimentin and decreased E-cadherin, detectable at both transcriptional and translational levels.